Bone quality and healing in a swine vascularized bone allotransplantation model using cyclosporine-based immunosuppression therapy.
Although vascularized bone and joint allotransplantation is a promising new treatment option for reconstructing large bone defects, the need for immunosuppressive agents to prevent rejection in these procedures poses a major problem. This problem stems from the fact that several of these agents can cause harmful side effects, such as alterations in bone quality and healing. Therefore, the purpose of this study was to determine what effect the commonly used immunosuppressant regimen cyclosporine A-based combination therapy has on bone quality and healing. In 10 pigs, vascularized bone allografts with skin and muscle components (osteomyocutaneous free flaps) were transplanted from size-matched donor animals. Recipient animals received oral cyclosporine A/mycophenolate mofetil/prednisone therapy for 90 days. Bone quality was studied before and after transplantation by measuring the bone's acoustic velocity and density and calculating the bone's elastic coefficient. Bone healing was assessed using radiographic analysis. Four animals were lost as a result of graft rejection or immunosuppression-related complications before the 90-day endpoint of the study. Although bone specimens taken from the six animals that completed the 90-day protocol had histological signs of rejection, they all seemed to have normal bone healing. Posttransplant bone density values were significantly decreased (p < 0.05) (1544.7 +/- 47.5 kg/m3) as compared with pretransplant values (1722.7 +/- 44.1 kg/m3). Results of the acoustic velocity and elastic coefficients measurements showed a significant decrease (p < 0.05) in posttransplant values (from 3503.0 +/- 165.1 meters/sec to 2963.0 +/- 54.6 meters/sec and from 21.6 +/- 2.2 GPa to 13.6 +/- 0.5 GPa, respectively), indicating diminished bone quality. The findings indicate that cyclosporine A/mycophenolate mofetil/prednisone combination therapy is ineffective in preventing bone rejection, that it decreases bone quality, and that it is associated with systemic toxicity, suggesting that this immunosuppressive regimen at the doses used in this study is not ideal for vascularized bone allotransplantation procedures.
Vossen
Marieke
M
Department of Surgery, University of Louisville, Louisville, Ky, USA.
Edelstein
Jean
J
Majzoub
Ramsey K
RK
Maldonado
Claudio
C
Perez-Abadia
Gustavo
G
Voor
Michael J
MJ
Orhun
Haldun
H
Tecimer
Taskin
T
Francois
Cedric
C
Kon
Moshe
M
Barker
John H
JH
D000818:Animals; D001706:Biopsy; D015519:Bone Density; D016025:Bone Transplantation / Q000502:physiology*; D016572:Cyclosporine / Q000627:therapeutic use*; D004548:Elasticity; D005552:Forelimb / Q000000981:diagnostic imaging / Q000601:surgery*; D006084:Graft Rejection / Q000473:pathology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011182:Postoperative Care; D011859:Radiography; D011884:Radius / Q000000981:diagnostic imaging / Q000473:pathology* / Q000637:transplantation; D013524:Surgical Flaps; D013552:Swine; D014184:Transplantation, Homologous; D014457:Ulna / Q000601:surgery; D014945:Wound Healing
D007166:Immunosuppressive Agents; D016572:Cyclosporine